Rikki M Tanner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/674241/publications.pdf

Version: 2024-02-01

41 papers 1,575 citations

279701 23 h-index 302012 39 g-index

41 all docs

41 docs citations

41 times ranked

3002 citing authors

#	Article	IF	CITATIONS
1	Visit-to-Visit Variability of Blood Pressure and Cardiovascular Disease and All-Cause Mortality. Hypertension, 2014, 64, 965-982.	1.3	196
2	Prevalence of Apparent Treatment-Resistant Hypertension among Individuals with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1583-1590.	2.2	130
3	Generalizability of SPRINT Results toÂtheÂU.S. Adult Population. Journal of the American College of Cardiology, 2016, 67, 463-472.	1.2	125
4	Epidemiology of Obesity, the Metabolic Syndrome, and Chronic Kidney Disease. Current Hypertension Reports, 2012, 14, 152-159.	1.5	91
5	Racial and Gender Differences in Stroke Severity, Outcomes, and Treatment in Patients with Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, e255-e261.	0.7	87
6	Waist Circumference, Body Mass Index, and ESRD in the REGARDS (Reasons for Geographic and Racial) Tj ETQq0	0.0 rgBT /	Oyerlock 10
7	Obesity, metabolic health, and the risk of end-stage renal disease. Kidney International, 2015, 87, 1216-1222.	2.6	78
8	Association of the Metabolic Syndrome With Atrial Fibrillation Among United States Adults (from the) Tj ETQq0 (Cardiology, 2011, 108, 227-232.	0 0 rgBT /C 0.7	Overlock 10 Ti 66
9	Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg. Circulation, 2017, 136, 798-812.	1.6	60
10	Association Between Sleep Apnea and Blood Pressure Control Among Blacks. Circulation, 2019, 139, 1275-1284.	1.6	53
11	Incident ESRD and Treatment-Resistant Hypertension: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. American Journal of Kidney Diseases, 2014, 63, 781-788.	2.1	46
12	Prevalence of Masked Hypertension and Its Association With Subclinical Cardiovascular Disease in African Americans: Results From the Jackson Heart Study. Journal of the American Heart Association, 2016, 5, e002284.	1.6	40
13	Pharmacogenetic Associations of MMP9 and MMP12 Variants with Cardiovascular Disease in Patients with Hypertension. PLoS ONE, 2011, 6, e23609.	1.1	38
14	The association between vitamin B12, albuminuria and reduced kidney function: an observational cohort study. BMC Nephrology, 2015, 16, 7.	0.8	35
15	Cardiovascular Health and Incident Hypertension in Blacks. Hypertension, 2017, 70, 285-292.	1.3	33
16	Association of Daytime and Nighttime Blood Pressure With Cardiovascular Disease Events Among African American Individuals. JAMA Cardiology, 2019, 4, 910.	3.0	33
17	Declines in coronary heart disease incidence and mortality among middle-aged adults with and without diabetes. Annals of Epidemiology, 2014, 24, 581-587.	0.9	32
18	Association between 24-hour blood pressure variability and chronic kidney disease: a cross-sectional analysis of African Americans participating in the Jackson heart study. BMC Nephrology, 2015, 16, 84.	0.8	30

#	Article	IF	CITATIONS
19	Black–White Differences in Cardiovascular Disease Mortality: A Prospective US Study, 2003–2017. American Journal of Public Health, 2020, 110, 696-703.	1.5	29
20	Adherence to antihypertensive medications and associations with blood pressure among African Americans with hypertension in the Jackson Heart Study. Journal of the American Society of Hypertension, 2017, 11, 581-588.e5.	2.3	28
21	Whiteâ€Coat Effect Among Older Adults: Data From the Jackson Heart Study. Journal of Clinical Hypertension, 2016, 18, 139-145.	1.0	26
22	Associations of Blood Pressure Dipping Patterns With Left Ventricular Mass and Left Ventricular Hypertrophy in Blacks: The Jackson Heart Study. Journal of the American Heart Association, 2017, 6, .	1.6	26
23	Atrial fibrillation and incident end-stage renal disease: The REasons for Geographic And Racial Differences in Stroke (REGARDS) study. International Journal of Cardiology, 2015, 185, 219-223.	0.8	24
24	Primary Care Physician Perspectives on Barriers to Statin Treatment. Cardiovascular Drugs and Therapy, 2017, 31, 303-309.	1.3	24
25	Apparent Treatment-resistant Hypertension Among Individuals with History of Stroke or Transient Ischemic Attack. American Journal of Medicine, 2015, 128, 707-714.e2.	0.6	23
26	Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in) Tj ETQq0 0	0 rgBT /C	verlock 10 Tf
27	Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group. American Journal of Hypertension, 2019, 32, 1146-1153.	1.0	17
28	The role of cystatin-C in the confirmation of reduced glomerular filtration rate among the oldest old. Archives of Medical Science, 2016, 1, 55-67.	0.4	16
29	Chronic kidney disease and incident apparent treatmentâ€resistant hypertension among blacks: Data from the Jackson Heart Study. Journal of Clinical Hypertension, 2017, 19, 1117-1124.	1.0	13
30	Stress and Depression Are Associated With Life's Simple 7 Among African Americans With Hypertension: Findings From the Jackson Heart Study. American Journal of Hypertension, 2021, 34, 1311-1321.	1.0	11
31	Secular changes in rates of coronary heart disease, fatal coronary heart disease, and out-of-hospital fatal coronary heart disease. International Journal of Cardiology, 2014, 174, 436-439.	0.8	9
32	Prevalence of Eligibility Criteria for the Systolic Blood Pressure Intervention Trial in US Adults Among Excluded Groups: Age < 50ÂYears, Diabetes Mellitus, or a History of Stroke. Journal of the American Heart Association, 2016, 5, .	1.6	9
33	Cardiovascular Health and Transition From Controlled Blood Pressure to Apparent Treatment Resistant Hypertension. Hypertension, 2020, 76, 1953-1961.	1.3	8
34	Ambulatory Blood Pressure Phenotypes in Adults Taking Antihypertensive Medication with and without CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 501-510.	2.2	7
35	A 6-CpG validated methylation risk score model for metabolic syndrome: The HyperGEN and GOLDN studies. PLoS ONE, 2021, 16, e0259836.	1.1	7
36	Genetic Contributors of Incident Stroke in 10,700 African Americans With Hypertension: A Meta-Analysis From the Genetics of Hypertension Associated Treatments and Reasons for Geographic and Racial Differences in Stroke Studies. Frontiers in Genetics, 2021, 12, 781451.	1.1	7

#	Article	IF	CITATIONS
37	Addressing Stroke Risk Factors in Black and White Americans: Findings from the National Health and Nutrition Examination Survey, 2009-2010. Ethnicity and Disease, 2016, 26, 9.	1.0	6
38	Prevalence and Characteristics of Systolic Blood Pressure Thresholds in Individuals 60 Years or Older. JAMA Internal Medicine, 2014, 174, 1397.	2.6	4
39	Low-density lipoprotein cholesterol levels among individuals experiencing statin-associated symptoms: Data from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Journal of Clinical Lipidology, 2020, 14, 720-729.	0.6	2
40	Genomics of Postprandial Lipidomics in the Genetics of Lipid-Lowering Drugs and Diet Network Study. Nutrients, 2021, 13, 4000.	1.7	2
41	Validation of an Albuminuria Self-assessment Tool in the Multi-Ethnic Study of Atherosclerosis (MESA). Ethnicity and Disease, 2015, 25, 427.	1.0	0